Futamura, Manabu http://orcid.org/0000-0001-5622-8352
Nakayama, Takahiro http://orcid.org/0000-0002-3713-1624
Yoshinami, Tetsuhiro
Oshiro, Chiya
Ishihara, Mikiya http://orcid.org/0000-0002-7581-2615
Morita, Midori http://orcid.org/0000-0003-4083-4432
Watanabe, Akira
Tanigichi, Azusa
Tsukabe, Masami
Shimoda, Masafumi
Nitta, Kanae
Chihara, Yoko
Yasojima, Hiroyuki
Ouchi, Yoshimi
Tokumaru, Yoshihisa http://orcid.org/0000-0003-2481-7739
Masuda, Norikazu http://orcid.org/0000-0002-7302-0278
Article History
Received: 31 January 2023
Accepted: 10 July 2023
First Online: 24 July 2023
Declarations
:
: MF—remuneration: Chugai, Taiho, Kaken-Seiyaku, Nippon-Kayaku, Daiichi-Sankyo, AstraZeneca, Pfizer, Eli Lilly, and Eisai. TN—remuneration: Chugai, Daiichi-Sankyo, Eli Lilly, Nippon-Kayaku, and Pfizer. TY—remuneration: Chugai, Pfizer, Eli Lilly, Eisai, Daiichi Sankyo, AstraZeneca, and Taiho. MI—remuneration: Daichi-Sankyo, Eisai, Chugai, Ono, MSD, AstraZeneca, and Eli Lilly. NM—remuneration: Chugai, AstraZeneca, Daiichi-Sankyo, Eisai, Kyowa-Hakko-Kirin, MSD, Novartis, Pfizer, and Sanofi.